The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.
Debulking, or lowering the tumor load, might provide over all survival benefits for men diagnosed with prostate cancer.
According to the results of the STAMPEDE trial.1 adding radiotherapy (radiation) to the current standard-of-care androgen deprivation therapy (ADT of hormone therapy) did not improve the overall survival in all men who are newly diagnosed metastatic prostate cancer.
Developing or being diagnosed with Prostate Cancer and having bone metastases is not good news.
Metformin is an inexpensive drug that might be able to be used with men with advanced prostate cancer who are on hormone therapy (ADT).
Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer.
There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.
Treatment modalities vary for men diagnosed with pathologic lymph node-positive (pN1) prostate cancer. Understanding current treatment patterns and their outcomes can help provide you with insight and direction in your decision-making.